Menu
Currency
GWAS Study

Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease.

Nielsen JB, Rom O, Surakka I et al.

33339817 PubMed ID
GWAS Study Type
196874 Participants
48 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

NJ
Nielsen JB
RO
Rom O
SI
Surakka I
GS
Graham SE
ZW
Zhou W
RT
Roychowdhury T
FL
Fritsche LG
GT
Gagliano Taliun SA
SC
Sidore C
LY
Liu Y
GM
Gabrielsen ME
SA
Skogholt AH
WB
Wolford B
OW
Overton W
ZY
Zhao Y
CJ
Chen J
ZH
Zhang H
HW
Hornsby WE
AA
Acheampong A
GA
Grooms A
SA
Schaefer A
ZG
Zajac GJM
VL
Villacorta L
ZJ
Zhang J
BB
Brumpton B
LM
Løset M
RV
Rai V
LP
Lundegaard PR
OM
Olesen MS
TK
Taylor KD
PN
Palmer ND
CY
Chen YD
CS
Choi SH
LS
Lubitz SA
EP
Ellinor PT
BK
Barnes KC
DM
Daya M
RN
Rafaels N
WS
Weiss ST
LJ
Lasky-Su J
TR
Tracy RP
VR
Vasan RS
CL
Cupples LA
MR
Mathias RA
YL
Yanek LR
BL
Becker LC
PP
Peyser PA
BL
Bielak LF
SJ
Smith JA
AS
Aslibekyan S
HB
Hidalgo BA
AD
Arnett DK
IM
Irvin MR
WJ
Wilson JG
MS
Musani SK
CA
Correa A
RS
Rich SS
GX
Guo X
RJ
Rotter JI
KB
Konkle BA
JJ
Johnsen JM
AA
Ashley-Koch AE
TM
Telen MJ
SV
Sheehan VA
BJ
Blangero J
CJ
Curran JE
PJ
Peralta JM
MC
Montgomery C
SW
Sheu WH
CR
Chung RH
SK
Schwander K
NS
Nouraie SM
GV
Gordeuk VR
ZY
Zhang Y
KC
Kooperberg C
RA
Reiner AP
JR
Jackson RD
BE
Bleecker ER
MD
Meyers DA
LX
Li X
DS
Das S
YK
Yu K
LJ
LeFaive J
SA
Smith A
BT
Blackwell T
TD
Taliun D
ZS
Zollner S
FL
Forer L
SS
Schoenherr S
FC
Fuchsberger C
PA
Pandit A
ZM
Zawistowski M
KS
Kheterpal S
BC
Brummett CM
NP
Natarajan P
SD
Schlessinger D
LS
Lee S
KH
Kang HM
CF
Cucca F
HO
Holmen OL
ÅB
Åsvold BO
BM
Boehnke M
KS
Kathiresan S
AG
Abecasis GR
CY
Chen YE
WC
Willer CJ
HK
Hveem K
Chapter II

Abstract

Summary of the research findings

Pharmaceutical drugs targeting dyslipidemia and cardiovascular disease (CVD) may increase the risk of fatty liver disease and other metabolic disorders. To identify potential novel CVD drug targets without these adverse effects, we perform genome-wide analyses of participants in the HUNT Study in Norway (n = 69,479) to search for protein-altering variants with beneficial impact on quantitative blood traits related to cardiovascular disease, but without detrimental impact on liver function. We identify 76 (11 previously unreported) presumed causal protein-altering variants associated with one or more CVD- or liver-related blood traits. Nine of the variants are predicted to result in loss-of-function of the protein. This includes ZNF529:p.K405X, which is associated with decreased low-density-lipoprotein (LDL) cholesterol (P = 1.3 × 10-8) without being associated with liver enzymes or non-fasting blood glucose. Silencing of ZNF529 in human hepatoma cells results in upregulation of LDL receptor and increased LDL uptake in the cells. This suggests that inhibition of ZNF529 or its gene product should be prioritized as a novel candidate drug target for treating dyslipidemia and associated CVD.

76,081 European ancestry individuals, 127,395 Japanese ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

196874
Total Participants
GWAS
Study Type
No
Replicated
European, East Asian
Ancestry
Norway, Japan, Italy
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.